Zio XT ECG Monitoring System vs Cardiomo

Direct competitors — feature-level head-to-head below. Comparability 85/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by iRhythm Technologies
VS
by Cardiomo, Inc.

AI Verdict

These two tools are highly comparable, both offering AI-powered wearable ECG monitoring for cardiac health. Zio XT focuses on extended, single-lead ECG monitoring with a strong emphasis on FDA-cleared AI and expert review for diagnosis, while Cardiomo provides a broader vital sign monitoring approach with real-time alerts and additional features like fall detection.

Choose Zio XT ECG Monitoring System if…

Choose Zio XT if you need a highly accurate, FDA-cleared, long-term continuous ECG monitoring solution for up to 14 days, particularly when a definitive diagnosis of arrhythmias is crucial and retesting needs to be minimized. Its water-resistant design and lack of external wires enhance patient comfort and compliance, making it suitable for patients who need to maintain normal daily activities during monitoring. It is also beneficial for integrating ECG data with physical activity levels for a comprehensive understanding of cardiac health in rehabilitation settings.

View Zio XT ECG Monitoring System →

Choose Cardiomo if…

Choose Cardiomo if you require continuous, real-time remote monitoring of multiple vital signs (ECG, heart rate, respiration, skin temperature) with immediate AI-powered alerts for both patients and caregivers. This tool is ideal for proactive management of cardiovascular diseases, especially for individuals who might benefit from timely notifications of potential cardiac events or falls, and for remote care of elderly patients. Its focus on real-time alerts and caregiver notifications makes it well-suited for situations where immediate intervention based on vital sign deviations is critical.

View Cardiomo →

When choosing between the Zio XT ECG Monitoring System and Cardiomo, physicians should consider their primary monitoring needs and patient population. The Zio XT system excels in extended, single-lead ECG monitoring for up to 14 days, making it particularly suitable for comprehensive arrhythmia detection and diagnosis in patients requiring prolonged observation. Its FDA-cleared AI and expert review process provide a robust solution for detailed cardiac event analysis. The key practical difference lies in Zio XT’s focus on a single-lead ECG for diagnostic purposes over a longer duration, supported by a well-defined reporting structure.

Cardiomo, on the other hand, offers broader vital sign monitoring, including ECG, heart rate, respiration, and skin temperature, with a focus on real-time alerts and notifications for cardiovascular events and even fall detection. This makes Cardiomo a strong contender for continuous, remote monitoring in populations where multiple vital signs are critical, such as geriatrics, or for patients who may benefit from immediate alerts to caregivers. Physicians prioritizing a comprehensive, multi-parameter view with real-time alerting for ongoing patient management, rather than solely extended diagnostic ECG, would find Cardiomo more aligned with their needs.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Zio XT ECG Monitoring System Cardiomo
Pricing Contact for pricing Contact for pricing
Deployment Cloud-based (AWS EC2 platform), no on-premise hardware required. Cloud-based with wearable device and mobile app
BAA Available Yes AI-estimated Unknown
FDA Status Yes AI-estimated Unknown
HIPAA Yes AI-estimated Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Zio XT ECG Monitoring System

Zio XT emphasizes patient comfort with a wire-free, water-resistant design that can be worn for up to 14 days, allowing for normal daily activities including showering. While some users report skin irritation, the overall design aims for minimal disruption and high patient compliance. Cardiomo also offers a wearable patch and mobile app, but specific details on comfort and patient experience are less extensively highlighted in the provided information, though it does mention being waterproof and having a long battery life.

Clinical Value

Zio XT ECG Monitoring System

Zio XT has extensive clinical validation, with over 135 original scientific manuscripts and multiple studies demonstrating its high diagnostic yield for various arrhythmias, often outperforming traditional Holter monitors. It is FDA-cleared and its AI algorithm is overseen by accredited cardiac physiologists. Cardiomo states it is a medical-grade device with AI-powered disease detection and has received ISO 13485 certification and CE Mark Class IIa, but the breadth and depth of its published clinical validation studies are not as clearly articulated as Zio XT's.

Pricing & Value

Tie

Both tools require contacting for current pricing, indicating a lack of public transparency. Zio XT provides some historical Medicare rates and a UK cost, along with financial assistance programs. Cardiomo previously offered a device at $200 with a $10 monthly subscription. Without current, directly comparable pricing or detailed cost-effectiveness studies for both, it's difficult to definitively declare a winner in terms of overall value.

Enterprise Readiness

Zio XT ECG Monitoring System

Zio XT is deployed on a cloud-based AWS EC2 platform and is HIPAA compliant, indicating a robust infrastructure for enterprise use. iRhythm also has established reimbursement arrangements with CMS and commercial payors, and its clinical centers are CMS-certified IDTFs, demonstrating a strong readiness for integration into healthcare systems. Cardiomo is also cloud-based and HIPAA compliant, but lacks the detailed information on established enterprise-level partnerships or specific integration capabilities.

Innovation

Zio XT ECG Monitoring System

Zio XT utilizes a proprietary, FDA-cleared deep-learned AI algorithm for ECG data analysis and offers continuous monitoring for up to 14 days, a longer period than traditional Holter monitors, with a wire-free, water-resistant design. The company also continues to innovate with newer generations of the Zio monitor. Cardiomo also features AI-powered disease detection and continuous vital sign monitoring, including fall detection, but Zio XT's FDA clearance for its AI and documented longer monitoring duration give it an edge in proven innovation.

Support & Docs

Zio XT ECG Monitoring System

iRhythm provides comprehensive support for Zio XT, including a clinical reference manual, instructions for use, and 24/7 customer care. They also offer resources for billing and reimbursement, and a dedicated clinical library with extensive evidence. While Cardiomo likely offers support, the available information does not detail the breadth and depth of its documentation and customer support services to the same extent as Zio XT.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Zio XT ECG Monitoring System Cardiomo
Name Zio XT ECG Monitoring System Cardiomo
Company iRhythm Technologies Cardiomo, Inc.
Monitoring Duration Up to 14 days Up to 7-10 days (battery life)
Key Monitoring Parameters Single-lead ECG ECG, heart rate, respiration, skin temperature
AI Algorithm Proprietary, FDA-cleared deep-learned AI algorithm for ECG data analysis AI-powered disease detection (arrhythmias, cardiovascular events)
Patient Interaction Patient-activated button for symptomatic event logging Real-time alerts and notifications, Mobile application (Android and iOS)
Additional Features Water-resistant design, no external leads or wires Fall detection

Videos

Demos, reviews, and walkthroughs featuring Zio XT ECG Monitoring System and Cardiomo.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

The Zio XT system is designed for ease of use, with a single-use, wire-free, water-resistant patch that patients can apply themselves and wear for up to 14 days, minimizing disruption to daily activities and potentially reducing the need for multiple outpatient appointments. While there may be an initial learning curve for staff compared to traditional Holter monitors, studies suggest Zio XT can lead to a shorter time to results and higher arrhythmia detection rates. Cardiomo also offers a medical-grade wearable patch for continuous monitoring, with data transmitted via Bluetooth to a mobile app and then to cloud storage, and aims to reduce healthcare professional involvement.
Cardiology-specific EHR systems are designed to handle the diagnostic depth and data flow of cardiovascular medicine, including integrating data from wearable cardiac monitoring devices. While both tools are cloud-based, the specifics of their EHR integration depth are not detailed. Effective EHR integration should allow for automated data ingestion, AI-powered triage of alerts, mobile-enabled clinical review, and synchronization of data and billing documentation to avoid data silos and improve efficiency.
The Zio XT system utilizes an FDA-cleared deep-learned AI algorithm for ECG data analysis and has demonstrated high diagnostic yield for cardiac arrhythmias compared to Holter monitors. One study indicated Zio XT had 99% sensitivity and 100% specificity in detecting AF. Cardiomo claims 99.2% clinical accuracy, validated through clinical studies, and its proprietary algorithms are trained to detect arrhythmias and other cardiac events.
Zio XT is indicated for patients who may be asymptomatic or experience transient symptoms like palpitations, dizziness, or syncope, and has shown effectiveness in detecting AF in previously undiagnosed adults over 75 with hypertension. Cardiomo is designed for continuous and remote heart health monitoring, providing timely alerts to users and caregivers, which could be beneficial for geriatrics or patients requiring ongoing surveillance.
iRhythm Technologies emphasizes the quality of the Zio report, stating it's analyzed by their AI algorithm and overseen by qualified cardiac physiologists, with 99.9% clinician agreement, suggesting robust support for report interpretation. Cardiomo's system provides real-time alerts and notifications to users and caregivers, and can send messages directly to healthcare consultants, indicating a support system for critical events.
While specific audit-trail features for Cardiomo are not detailed, for Zio XT, the end-of-wear report provides details on wear time and analyzable time, and representative ECG strips are arranged by clinical significance with additional information. Generally, robust cardiology information systems should include user authentication and event logging to identify individuals accessing patient data and to create reports of user activity for HIPAA compliance.

Backers

Who funded each tool's parent company.

Cardiomo

AI Tool Finder
AI-powered search. Results may not be comprehensive.